Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.38 |
| ▸ | MLKL | Q8NB16 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | CBFB | Q13951 | 2/20 | 0.35 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066546 | 0.89 | NPY5R (0.39) | SCN10AMLKLTRPA1CBFBPDE2A | |
| SCHEMBL14770499 | 0.87 | MLKL (0.44) | MLKLACP1ALPLALPIALPG | |
| SCHEMBL12066547 | 0.85 | SCN10A (0.43) | SCN10AMLKLTRPA1MTORNR3C2 | |
| SCHEMBL14762836 | 0.85 | MLKL (0.48) | SCN10AMLKLTRPA1PDE2AALPL | |
| SCHEMBL14762782 | 0.83 | SCN10A (0.43) | SCN10AMLKLTRPA1PDE2AALPL | |
| SCHEMBL12065615 | 0.83 | SCN10A (0.38) | SCN10AMLKLTRPA1MTORNR3C2 | |
| SCHEMBL12065255 | 0.83 | SCN10A (0.40) | SCN10AMLKLTRPA1NR3C2PDE2A | |
| SCHEMBL12066063 | 0.82 | SCN10A (0.38) | SCN10AMLKLTRPA1MTORNR3C2 | |
| SCHEMBL12065641 | 0.81 | ALPL (0.38) | SCN10AMLKLTRPA1MTORRUNX1 | |
| SCHEMBL12065659 | 0.81 | SCN10A (0.39) | SCN10AMLKLTRPA1NR3C2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | SCN10A 85/4885MLKL 2378/4885TRPA1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.